ZBIO News and Press, ProShares UltraPro Short NASDAQ Biotechnology From 01/06/26

2026-01-06 04:58:39 ET The last time I spoke about Zenas BioPharma, Inc. ( ZBIO ), it was regarding a Seeking Alpha article entitled " Zenas: Differentiated B-Cell Targeting Drug With Q3 of 2025 Catalys t". Regarding this article, I went over the fact that the company wa...

2026-01-05 16:05:29 ET from Morgan Stanley issued a price target of $19.00 for ZBIO on 2026-01-05 20:39:57. The adjusted price target was set to $19.00. At the time of the announcement, ZBIO was trading at $16.61. The overall price target consensus is at $43.33 with high...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 4.2% to $2.635 on volume of 313,129,849 shares Datavault AI Inc. (DVLT) rose 41.1% to $1.4255 on volume of 273,382,842 shares Hyperscale Data Inc. (GPUS) fell 6.7% to $0.2547 on vo...

2026-01-05 09:17:10 ET More on Zenas BioPharma, Inc. Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal Best Quant-rated small- and mid-cap healthcare stocks as LLY hits $1T in market c...

- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically significant activity on all four key secondary efficacy endpoints - - Obexelimab w...

2025-12-22 05:15:03 ET Citigroup analyst issues BUY recommendation for ZBIO on December 22, 2025 10:39AM ET. The previous analyst recommendation was Buy. ZBIO was trading at $36.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...

- Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE - - Zenas acquired the exclusive right to develop, manufacture and commercialize orelabrutinib in the field of Multiple Sclerosis globally, and non-oncology fields in al...

2025-12-15 04:18:58 ET Thesis Zenas BioPharma ( ZBIO ) stock has seen a lot of positive momentum over the past year. Year to date, the stock is up 395% and has heavily outperformed the S&P. Now, the company obviously has two late-stage assets in obexelimab and orelabrutinib....

2025-12-04 16:38:09 ET More on markets 2026 Prediction: A Tapped-Out Consumer Could Bring The Recession And Market Correction A Weaker Dollar As The Fed Moves Toward Neutral: 3 Calls For FX Feels Normal, But Bounded By Extremes: 3 Calls For Rates Top 5 macro ...

2025-11-21 11:03:32 ET More on healthcare TG Therapeutics: Concerns About Slowing Growth And New Competition TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing Eli Lilly: This Breakout Rally Has More Room To Run Lilly market cap excee...